REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) will conduct a conference call on August 3, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022, along with recent operational highlights. Investors and analysts can register for the event via the provided links. REGENXBIO is focused on gene therapy, employing its NAV Technology Platform, which includes over 100 AAV vectors. The company aims to advance five AAV therapeutics into pivotal-stage or commercial products by 2025.
- Focused on advancing five AAV therapeutics into pivotal-stage or commercial products by 2025.
- None.
ROCKVILLE, Md., Aug. 1, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022, and recent operational highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on particpating are advised to join 15 minutes prior to the start time.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-3-to-discuss-second-quarter-2022-financial-results-and-recent-operational-highlights-301596706.html
SOURCE REGENXBIO Inc.
FAQ
When will REGENXBIO announce its Q2 2022 financial results?
What time is the REGENXBIO conference call?
What is REGENXBIO's goal for 2025?
How can investors participate in the conference call?
